6 days Ago By ABMN Staff
Federated Hermes Inc. boosted its stake in shares of Entrada Therapeutics, Inc. ( NASDAQ:TRDA – Free Report ) by 3,104.
3% in the 4th quarter, Holdings Channel.com reports. The firm owned 99,814 shares of the company’s stock after buying an additional 96,699 shares during the quarter.
Federated Hermes Inc.’s holdings in Entrada Therapeutics were worth $1,726,000 as of its most recent filing with the Securities and Exchange Commission (SEC). A number of other hedge funds have also recently bought and sold shares of TRDA.
Geode Capital Management LLC raised its stake in shares of Entrada Therapeutics by 8.8% in the third quarter. Geode Capital Management LLC now owns 576,451 shares of the company’s stock valued at $9,214,000 after purchasing an additional 46,512 shares in the last quarter.
Barclays PLC increased its holdings in Entrada Therapeutics by 210.6% in the 3rd quarter. Barclays PLC now owns 45,110 shares of the company’s stock valued at $720,000 after buying an additional 30,585 shares during the period.
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Entrada Therapeutics by 34.7% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,156 shares of the company’s stock valued at $226,000 after buying an additional 3,644 shares in the last quarter.
State Street Corp lifted its holdings in shares of Entrada Therapeutics by 5.5% during the 3rd quarter. State Street Corp now owns 469,601 shares of the company’s stock worth $7,504,000 after acquiring an additional 24,385 shares during the period.
Finally, SG Americas Securities LLC boosted its position in shares of Entrada Therapeutics by 44.0% during the 4th quarter. SG Americas Securities LLC now owns 14,036 shares of the company’s stock valued at $243,000 after acquiring an additional 4,291 shares in the last quarter.
86.39% of the stock is owned by institutional investors. Entrada Therapeutics Stock Performance Shares of NASDAQ TRDA opened at $7.
92 on Tuesday. Entrada Therapeutics, Inc. has a 52-week low of $7.
10 and a 52-week high of $21.79. The business has a fifty day moving average of $10.
69 and a two-hundred day moving average of $14.81. The stock has a market cap of $297.
75 million, a PE ratio of 4.98 and a beta of 0.04.
Analyst Ratings Changes Separately, HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Entrada Therapeutics in a research note on Monday, March 31st. Get Our Latest Stock Analysis on Entrada Therapeutics Entrada Therapeutics Profile ( Free Report ) Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases.
Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. Featured Articles Want to see what other hedge funds are holding TRDA? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Entrada Therapeutics, Inc. ( NASDAQ:TRDA – Free Report ). Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
